{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:25:37Z","timestamp":1772119537913,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100018441","name":"Japan Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018441","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s10147-024-02652-7","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T09:07:57Z","timestamp":1731402477000},"page":"17-26","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical Oncology"],"prefix":"10.1007","volume":"30","author":[{"given":"Kazuhisa","family":"Nakashima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Harashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rena","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuhei","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Iino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Akechi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiyo K.","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Satomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako Eguchi","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Noda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Higashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Okita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Aogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,12]]},"reference":[{"key":"2652_CR1","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","volume":"24","author":"B Bloechl-Daum","year":"2006","unstructured":"Bloechl-Daum B, Deuson RR, Mavros P et al (2006) Delayed nausea and vomiting continue to reduce patients\u2019 quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472\u20134478","journal-title":"J Clin Oncol"},{"key":"2652_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","volume":"13","author":"CC Sun","year":"2005","unstructured":"Sun CC, Bodurka DC, Weaver CB et al (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219\u2013227","journal-title":"Support Care Cancer"},{"key":"2652_CR3","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/1097-0142(19900915)66:6<1124::AID-CNCR2820660608>3.0.CO;2-T","volume":"66","author":"R Epelbaum","year":"1990","unstructured":"Epelbaum R, Faraggi D, Ben-Arie Y et al (1990) Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 66:1124\u20131129","journal-title":"Cancer"},{"key":"2652_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T et al (2021) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for antiemesis. Int J Clin Oncol 26:1\u201317","journal-title":"Int J Clin Oncol"},{"key":"2652_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 88:105906","journal-title":"Int J Surg"},{"key":"2652_CR6","unstructured":"Kojimahara N, Nakayama T, Morizane T, et al (2017) Minds manual for Guideline 18 development 2017. Japan Council for Quality Health Care, Tokyo"},{"key":"2652_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a744","volume":"337","author":"R Jaeschke","year":"2008","unstructured":"Jaeschke R, Guyatt GH, Dellinger P et al (2008) Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 337:a744","journal-title":"BMJ"},{"key":"2652_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s005209900090","volume":"8","author":"AA Fauser","year":"2000","unstructured":"Fauser AA, Pizzocaro G, Schueller J et al (2000) A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting. Support Care Cancer 8:49\u201354","journal-title":"Support Care Cancer"},{"key":"2652_CR9","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1200\/JCO.2011.39.5558","volume":"30","author":"C Albany","year":"2012","unstructured":"Albany C, Brames MJ, Fausel C et al (2012) Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a Hoosier Oncology Group study. J Clin Oncol 30:3998\u20134003","journal-title":"J Clin Oncol"},{"key":"2652_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jnci.2017.05.001","volume":"29","author":"R Abdel-Malek","year":"2017","unstructured":"Abdel-Malek R, Abbas N, Shohdy KS et al (2017) Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy. J Egypt Natl Canc Inst 29:155\u2013158","journal-title":"J Egypt Natl Canc Inst"},{"key":"2652_CR11","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s00520-007-0255-6","volume":"15","author":"LH Einhorn","year":"2007","unstructured":"Einhorn LH, Brames MJ, Dreicer R et al (2007) Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer 15:1293\u20131300","journal-title":"Support Care Cancer"},{"key":"2652_CR12","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.ejca.2008.11.046","volume":"45","author":"K Jordan","year":"2009","unstructured":"Jordan K, Kinitz I, Voigt W et al (2009) Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 45:1184\u20131187","journal-title":"Eur J Cancer"},{"key":"2652_CR13","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1007\/s00520-012-1696-0","volume":"21","author":"IN Olver","year":"2013","unstructured":"Olver IN, Grimison P, Chatfield M et al (2013) Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy. Support Care Cancer 21:1561\u20131568","journal-title":"Support Care Cancer"},{"key":"2652_CR14","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s00520-014-2182-7","volume":"22","author":"S Hamada","year":"2014","unstructured":"Hamada S, Hinotsu S, Kawai K et al (2014) Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy. Support Care Cancer 22:2161\u20132166","journal-title":"Support Care Cancer"},{"key":"2652_CR15","first-page":"2837","volume":"24","author":"N Adra","year":"2016","unstructured":"Adra N, Albany C, Brames MJ et al (2016) Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study. Support Care Cancer 24:2837\u20132842","journal-title":"Support Care Cancer"},{"key":"2652_CR16","first-page":"1419","volume":"26","author":"T Ioroi","year":"2018","unstructured":"Ioroi T, Furukawa J, Kume M et al (2018) Phase II study of palonosetron, aprepitant and dexamethasone to prevent nausea and vomiting induced by multiple-day emetogenic chemotherapy. Support Care Cancer 26:1419\u20131423","journal-title":"Support Care Cancer"},{"key":"2652_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10637-017-0487-3","volume":"36","author":"S Bun","year":"2018","unstructured":"Bun S, Yonemori K, Akagi T et al (2018) Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy. Investig New Drugs 36:151\u2013155","journal-title":"Investig New Drugs"},{"key":"2652_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5649\/jjphcs.38.163","volume":"38","author":"W Suzuki","year":"2012","unstructured":"Suzuki W, Aoyama T, Sugita K et al (2012) Evaluation of prevention of the emetic effects with 3-day administration of aprepitant in multiple-day chemotherapy. Jpn J Pharm Health Care Sci 38:163\u2013169 (in Japanese)","journal-title":"Jpn J Pharm Health Care Sci"},{"key":"2652_CR19","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1345\/aph.1R396","volume":"46","author":"KI Kim","year":"2012","unstructured":"Kim KI, Lee DE, Cho I et al (2012) Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy. Ann Pharmacother 46:1637\u20131644","journal-title":"Ann Pharmacother"},{"key":"2652_CR20","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1200\/JCO.1993.11.12.2391","volume":"11","author":"SM Fox","year":"1993","unstructured":"Fox SM, Einhorn LH, Cox E et al (1993) Ondansetron versus ondansetron, dexamethasone, and chlorpromazine in the prevention of nausea and vomiting associated with multiple-day cisplatin chemotherapy. J Clin Oncol 11:2391\u20132395","journal-title":"J Clin Oncol"},{"key":"2652_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00520-006-0158-y","volume":"15","author":"J Herrstedt","year":"2007","unstructured":"Herrstedt J, Sigsgaard TC, Nielsen HA et al (2007) Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer 15:417\u2013426","journal-title":"Support Care Cancer"},{"key":"2652_CR22","first-page":"585","volume":"44","author":"K Uchiyama","year":"2017","unstructured":"Uchiyama K, Yamada M, Shiiba Y et al (2017) Determination of the effect of aprepitant and fosaprepitant for nausea in patients with oral cancer receiving combination chemotherapy with TPF. Gan To Kagaku Ryoho 44:585\u2013589 (in Japanese)","journal-title":"Gan To Kagaku Ryoho"},{"key":"2652_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1200\/JCO.1990.8.4.731","volume":"8","author":"LH Einhorn","year":"1990","unstructured":"Einhorn LH, Nagy C, Werner K et al (1990) Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 8:731\u2013735","journal-title":"J Clin Oncol"},{"key":"2652_CR24","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1097\/00000421-199108000-00013","volume":"14","author":"JD Hainsworth","year":"1991","unstructured":"Hainsworth JD, Omura GA, Khojasteh A et al (1991) Ondansetron (GR 38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapy. Am J Clin Oncol 14:336\u2013340","journal-title":"Am J Clin Oncol"},{"key":"2652_CR25","first-page":"995","volume":"24","author":"Y Ariyoshi","year":"1997","unstructured":"Ariyoshi Y, Nukariya N, Akasaka Y et al (1997) Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis. Gan To Kagaku Ryoho 24:995\u20131011 (in Japanese)","journal-title":"Gan To Kagaku Ryoho"},{"key":"2652_CR26","doi-asserted-by":"publisher","first-page":"542","DOI":"10.5649\/jjphcs.36.542","volume":"36","author":"T Aoyama","year":"2010","unstructured":"Aoyama T, Sugiyama H, Hiraoka T et al (2010) Evaluation of alternate-day administration of dexamethasone for prevention of nausea, vomiting and anorexia induced by daily administration of ifosfamide. Jpn J Pharm Health Care Sci 36:542\u2013548 (in Japanese)","journal-title":"Jpn J Pharm Health Care Sci"},{"key":"2652_CR27","first-page":"1879","volume":"19","author":"M Suminaga","year":"1992","unstructured":"Suminaga M, Furue H, Taguchi T et al (1992) Investigation of anti-emetic effect of ondansetron tablet in multiple doses on nausea and emesis associated with cisplatin. Gan To Kagaku Ryoho 19:1879\u20131890 (in Japanese)","journal-title":"Gan To Kagaku Ryoho"},{"key":"2652_CR28","first-page":"1359","volume":"19","author":"Y Akasaka","year":"1992","unstructured":"Akasaka Y, Taguchi T, Ota K et al (1992) Anti-emetic effect and safety of consecutive use of ondansetron injection in cisplatin-induced nausea and emesis. Gan To Kagaku Ryoho 19:1359\u20131374 (in Japanese)","journal-title":"Gan To Kagaku Ryoho"},{"key":"2652_CR29","first-page":"1063","volume":"22","author":"H Akaza","year":"1995","unstructured":"Akaza H, Machida T, Akasaka Y et al (1995) The antiemetic effect, safety and usefulness of tropisetron capsule in the treatment of nausea and vomiting induced by lower multiple dose of cisplatin. Gan To Kagaku Ryoho 22:1063\u20131072 (in Japanese)","journal-title":"Gan To Kagaku Ryoho"},{"key":"2652_CR30","unstructured":"Taketani Y, Yoshikawa H, Kinoshita K, et al (1996) The world of obstetrics and gynecology. 48:749\u2013760 (in Japanese)"},{"key":"2652_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134\u2013142","journal-title":"N Engl J Med"},{"key":"2652_CR32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242\u2013249","journal-title":"Lancet Oncol"},{"key":"2652_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4143\/crt.2017.577","volume":"51","author":"SY Jeon","year":"2019","unstructured":"Jeon SY, Han HS, Bae WK et al (2019) A randomized, double-blind, placebo-controlled study of the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: results of the Korean south west oncology group (KSWOG) study. Cancer Res Treat 51:90\u201397","journal-title":"Cancer Res Treat"},{"key":"2652_CR34","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00280-019-03868-5","volume":"84","author":"K Tanaka","year":"2019","unstructured":"Tanaka K, Inui N, Karayama M et al (2019) Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemother Pharmacol 84:147\u2013153","journal-title":"Cancer Chemother Pharmacol"},{"key":"2652_CR35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.ygyno.2020.01.004","volume":"156","author":"H Iihara","year":"2020","unstructured":"Iihara H, Shimokawa M, Hayasaki Y et al (2020) Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: a multi-institution phase II study. Gynecol Oncol 156:629\u2013635","journal-title":"Gynecol Oncol"},{"key":"2652_CR36","doi-asserted-by":"publisher","first-page":"e1066","DOI":"10.1002\/onco.13772","volume":"26","author":"C Sakai","year":"2021","unstructured":"Sakai C, Shimokawa M, Iihara H et al (2021) Low-dose olanzapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic malignancies: a prospective multicenter Phase II trial. Oncologist 26:e1066\u2013e1072","journal-title":"Oncologist"},{"key":"2652_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.21.01315","volume":"40","author":"A Hata","year":"2022","unstructured":"Hata A, Okamoto I, Inui N et al (2022) Randomized, double-blind, Phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE. J Clin Oncol 40:180\u2013188","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02652-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02652-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02652-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T13:02:40Z","timestamp":1735995760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02652-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,12]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["2652"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02652-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4806737\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,12]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kazuhisa Nakashima received honoraria from Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., and Eli Lilly Japan K.K. Eriko Satomi received honoraria from Shionogi & Co., Ltd. Masayuki Takeda received honoraria from Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., and Bayer. Takako Eguchi Nakajima received research funding from KBBM, Inc. and Takeda Pharmaceutical Co., Ltd. Junichi Nishimura received honoraria from Taiho Pharmaceutical Co., Ltd. Narikazu Boku received honoraria from Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K. Koji Matsumoto received honoraria from MSD K.K., Kyowa Kirin Co., Ltd., and Chugai Pharmaceutical Co., Ltd. as well as research funding from Daiichi Sankyo Co., Ltd., MSD K.K., Gilead Sciences, Inc., and Eli Lilly Japan K.K. Nobuyuki Yamamoto received honoraria from MSD K.K., Accuray Japan K.K., AstraZeneca K.K., Abbvie Inc., Amgen Inc., Ono Pharmaceutical Co., Ltd., Guardant Health Japan Corp., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Chugai Foundation for Innovative Drug Discovery Science, Lao Tsumura Co., Ltd., Terumo Corporation, Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Novartis AG, Pfzer Global Supply Japan Inc., Merck Biopharma Co., Ltd, Pfzer Global Supply Japan Inc., Merck Biopharma Co., Ltd., Janssen Pharmaceutical K.K., and USACO Corporation, as well as legal fees in case of lawsuit from Taiho Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan, Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Nippon Kayaku Co., Ltd., Prime Research Institute for Medical RWD, Inc., AstraZeneca K.K., and A2 Healthcare Corporation. Other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Formal consent was not required for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consented to the publication of this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}